According to the lawsuit, defendants throughout the Class Period created the false impression that they possessed reliable information pertaining to Cassava’s drug prospects and anticipated growth while also minimizing risk from a potential drug failure. Yet, in truth, Cassava’s repeated statements of confidence in simufilam, Cassava’s leading drug candidate, and reliance upon spinning the statistically insignificant data from the Phase 2 study fell short of the reality of simufilam’s potential; Cassava simply did not have a drug that was capable of abating the progression of Alzheimer’s Disease, even when attempting to treat only the mild and moderate cases.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Attorney Advertising. Prior results do not guarantee a similar outcome.
